Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From AbbVie Inc.

Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India

India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

Policy India

Pharma Past Propels Julie Brown To GSK’s CFO Position

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.

Executive Changes Leadership

Prestige Pulls Trastuzumab After EMA Knockback

Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.

Biosimilars Europe

Formycon Reveals Keytruda Biosimilar In The Works

Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Luminera
    • Mavupharma
    • Pharmacyclics, Inc.
    • Stemcentrx, Inc.
    • Syndesi Therapeutics SA
UsernamePublicRestriction

Register